Loading...
Loading...
EDIT| Name | Value |
|---|---|
| Revenues | 60.0M |
| Cost of Revenue | 1.5M |
| Gross Profit | 58.6M |
| Operating Expense | 82.5M |
| Operating I/L | -24.0M |
| Other Income/Expense | 5.1M |
| Interest Income | 5.1M |
| Pretax | -18.9M |
| Income Tax Expense | 10.3M |
| Net Income/Loss | -18.9M |
Editas Medicine, Inc. is a clinical stage genome editing company specializing in developing transformative genomic medicines for serious diseases. Their proprietary gene editing platform, based on CRISPR technology, is utilized to develop innovative treatments such as EDIT-101 for Leber Congenital Amaurosis 10, EDIT-102 for Usher Syndrome 2A, and EDIT-301 for sickle cell disease and transfusion-dependent beta-thalassemia. Additionally, the company is working on gene-edited cell therapies for various cancers and has research collaborations with industry leaders. Editas Medicine, Inc. generates revenue through the development and commercialization of gene editing medicines for a range of genetic disorders and cancers.
